Clik here to view.
EnvisionTEC与Somos®合作开发高性能材料
密歇根州迪尔伯恩 (美国商业资讯)–EnvisionTEC自豪地宣布与帝斯曼(DSM)旗下产品品牌、增材制造(additive manufacturing)材料研发领域的全球领导者Somos®建立合作关系。这份合作关系将让两家企业能够推进其技术进步并开发新的应用。 EnvisionTEC首席运营官John...
View ArticleClik here to view.
Clik here to view.
Opening of Mars, Incorporated Global Food Safety Center Signals Invitation...
MCLEAN, Va. & HUAIROU, China Mars, Incorporated announced today the opening of its Global Food Safety Center, a first-of-its-kind facility for pre-competitive research and training that aims to...
View ArticleClik here to view.
EOS imaging Announces Second Installation in Hong Kong
PARIS EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today that The Duchess of Kent Children’s Hospital has become the second hospital in...
View ArticleClik here to view.
EU Marketing Approval Granted for VivaGel® BV
MELBOURNE, Australia Starpharma (ASX: SPL) (OTCQX: SPHRY) today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief...
View ArticleClik here to view.
Clik here to view.
エンビジョンテックが高性能材料の開発でSomos®と提携
米ミシガン州ディアボーン (ビジネスワイヤ) — エンビジョンテックは、DSMの製品ブランドとして世界の付加製造向け材料開発をリードするSomos®との提携を発表します。この提携により、2社はそれぞれの技術を発展させ、新しいアプリケーションを開発できるようになります。...
View ArticleClik here to view.
武田薬品が来る国際骨髄腫ワークショップでイキサゾミブの臨床開発プログラムについて報告
ローマ （ビジネスワイヤ）– 武田薬品工業株式会社（TSE: 4502）は本日、2015年9月23～26日にイタリアのローマで開催される第15回国際骨髄腫ワークショップ（IMW 2015）の複数のポスターセッションで、イキサゾミブの臨床開発プログラムについて報告すると発表しました。 武田薬品Oncology Therapeutic Area...
View ArticleClik here to view.
武田在即将召开的国际骨髓瘤研讨会上介绍Ixazomib临床开发项目
罗马 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，将在第15届国际骨髓瘤研讨会(IMW 2015)的多个壁报分会场上介绍ixazomib 临床开发项目，此次研讨会将于2015年9月23至26日在意大利罗马召开。 武田肿瘤治疗领域部门副总裁Dixie-Lee Esseltine, MD,...
View ArticleClik here to view.
THERAVECTYS Appoints Dr. Jean-Pierre Bizzari to Board of Directors
PARIS THERAVECTYS, a Paris-based, fully-integrated discovery & clinical development company specialized in lentiviral vector-based therapeutic vaccines and T-cell therapies, is proud to announce...
View ArticleClik here to view.
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational...
DARMSTADT, Germany & NEW YORK Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy...
View ArticleClik here to view.
Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release...
HYDERABAD, India Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic...
View ArticleClik here to view.
Clik here to view.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone®...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502) today obtained the New Drug Application approval for Copaxone® Subcutaneous Injection 20 mg Syringe (generic name: glatiramer...
View ArticleClik here to view.
武田薬品: 多発性硬化症治療剤「コパキソン®皮下注20mgシリンジ」の日本における製造販売承認取得について
大阪 （ビジネスワイヤ） — 当社は、本日、多発性硬化症治療剤「コパキソン®皮下注20mgシリンジ」（一般名：グラチラマー酢酸塩、以下「コパキソン」）について、厚生労働省から製造販売承認を取得しましたのでお知らせします。 このSmart News Release（スマート・ニュース・リリース）にはマルチメディアのコンテンツが含まれています。リリース全文はこちらから：...
View ArticleClik here to view.
Sosei Subsidiary Heptares Awarded $5.5 Million Research & Development Grant...
TOKYO Sosei Group Corporation (“Sosei”; TOKYO:4565) is pleased to announce that its wholly-owned subsidiary Heptares Therapeutics (“Heptares”) has been awarded a grant from the National Institute on...
View ArticleClik here to view.
MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2...
KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV®...
View ArticleClik here to view.
Cynvenio Biosystems and ATGen Announce Strategic Partnership to Bring NK Vue...
LOS ANGELES & SEOUL, South Korea Cynvenio Biosystems, Inc., a diagnostics company dedicated to enabling the new era of individualized medicine for all cancer patients, and ATGen Global, a...
View ArticleClik here to view.
Quintiles Recognized as Phase IV Services Leader for Third Consecutive Year
RESEARCH TRIANGLE PARK, N.C. Quintiles has been named the market leader in Phase IV services for the third year in a row, according to the 2015 CRO Quality Benchmarking – Phase IV Service Providers...
View ArticleClik here to view.
Medacta Highlights Importance of Surgeon Education for the Anterior Approach...
LUGANO, Switzerland & CHICAGO This week, Medacta, a privately held, family-owned global leader in the design of innovative joint replacement and spine surgery products, celebrates a significant...
View Article